多单元技术授予美国专利涉及治疗哪家抗击病毒感染和癌症

StephenW

MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
PR Newswire
August 25, 2014: 08:51 AM ET

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer.  These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.

In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity.  Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells.  This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal.

Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge.  During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection.  In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFNγ) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal.

MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers.

Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma.  According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma.

Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need.   Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world.  Over 1 million cases of hepatocellular carcinoma are reported annually worldwide.  Current approaches for treatment of hepatocellular carcinoma are of limited efficacy.  According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years.

MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells.  MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer.  MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

StephenW

多单元技术授予美国专利涉及治疗哪家抗击病毒感染和癌症
美通社
2014年8月25日：上午08时51 ET

WOONSOCKET，扶轮社，2014年8月25日/新华美通/ - 多技术公司（场外交易代码：MCET）已发行的美国专利8809290包括新型药物组合物及其平台技术的重定向的免疫系统反应，以防止高毒力病毒感染和癌症。这些新的药物组合物，包括非编码的一倍的双链RNA（dsRNA）的分子和重组免疫球蛋白的肽（IGP）的分子表现出独特的免疫刺激活性，并呈现的肽抗原产生保护性的抗肿瘤和抗病毒免疫的免疫细胞的能力。

在小鼠癌症模型，MCT-465，dsRNA的治疗和MCT-475的组合，一个IGP的治疗，不仅引起动物的免疫系统，消除了植入肿瘤，但在再激发肿瘤细胞，开发任何新的肿瘤显示动物制定了保护性的抗肿瘤免疫力。肿瘤排斥和防止类似和新肿瘤变种被发现也可以与细胞因子产生细胞的特异性，整体扩张有关。这一发现表明抗肿瘤免疫细胞的剧目和免疫记忆在动物的发展扩大。

免疫小鼠的MCT-465和MCT-475导致了能够限制进一步的病毒感染性的挑战后续病毒复制的免疫应答的灌注。在病毒感染时，特定的免疫系统细胞开始增殖并分化限定于感染获得性免疫应答。在小鼠模型中，MCT-465和MCT-475的给药大大增强了干扰素γ的产生（IFNγ）和白细胞介素-2（IL-2）产生的病毒抗原特异性的T细胞产生显著降低病毒水平存在于动物。

多单元正在开发的MCT-465和MCT-475为B型肝炎病毒感染和丙型肝炎病毒感染的治疗，以及用于某些癌症的治疗。

慢性乙型肝炎和慢性丙型肝炎病毒感染是公认的全球主要因素增加肝癌的风险。据美国国家癌症研究所（NCI），慢性乙型肝炎病毒感染和慢性丙型肝炎病毒感染者约占30％〜40％的肝癌都报道美国的案件。

肝癌，原发性肝癌的最常见的形式中，治疗是一个重大的未满足的医疗需求。肝癌是癌症死亡的一个主要原因全世界，并且是世界第四大最常见的癌症。超过1万例肝癌，每年世界各地的报道。目前的方法治疗肝癌的疗效有限。据美国国立癌症研究所，只有16％的患者确诊为原发性肝癌存活超过5年时间。

多单元也正在开发的MCT-485，一个非常小的dsRNA的治疗，认为通过提供一种细胞毒性作用于具有最高肿瘤起始能力是癌变过程的一部分，例如癌症干细胞和肿瘤起始细胞只有那些细胞靶向癌症。 MCT-485似乎对细胞不直接参与的复发，发展及癌转移的过程没有任何影响。 MCT-485似乎会对肝癌细胞以优惠的生物活性，同时显示出对正常肝细胞没有影响。

关于多细胞技术公司

多细胞技术公司是一家临床阶段的生物制药企业，开发创新疗法和发现工具，主要多发性硬化症有关的疲劳和癌症的治疗。关于多细胞技术公司的更多信息，请访问http://www.multicelltech.com。